US5428156A - Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging - Google Patents

Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging Download PDF

Info

Publication number
US5428156A
US5428156A US08/042,249 US4224993A US5428156A US 5428156 A US5428156 A US 5428156A US 4224993 A US4224993 A US 4224993A US 5428156 A US5428156 A US 5428156A
Authority
US
United States
Prior art keywords
dota
compound
formula
teta
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US08/042,249
Inventor
Ronnie C. Mease
Leonard F. Mausner
Suresh C. Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brookhaven Science Associates LLC
Original Assignee
Associated Universities Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Associated Universities Inc filed Critical Associated Universities Inc
Priority to US08/042,249 priority Critical patent/US5428156A/en
Assigned to ASSOCIATED UNIVERSITIES, INC. reassignment ASSOCIATED UNIVERSITIES, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MAUSNER, LEONARD F., SRIVASTAVA, SURESH C., MEASE, RONNIE C.
Application granted granted Critical
Publication of US5428156A publication Critical patent/US5428156A/en
Assigned to BROOKHAVEN SCIENCE ASSOCIATES reassignment BROOKHAVEN SCIENCE ASSOCIATES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASSOCIATED UNIVERSITIES, INC.
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings

Abstract

A simple method for the synthesis of 1,4,7,10-tetraazacyclododecane N,N'N",N'"-tetraacetic acid and 1,4,8,11-tetraazacyclotetradecane N,N',N",N'"-tetraacetic acid involves cyanomethylating 1,4,7,10-tetraazacyclododecane or 1,4,8,11-tetraazacyclotetradecane to form a tetranitrile and hydrolyzing the tetranitrile. These macrocyclic compounds are functionalized through one of the carboxylates and then conjugated to various biological molecules including monoclonal antibodies. The resulting conjugated molecules are labeled with radiometals for SPECT and PET imaging and for radiotherapy.

Description

This invention was made with government support under contract number DE-AC02-76CH00016 between the U.S. Department of Energy and Associated Universities and NIH Grant CA-51958. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The invention relates to the synthesis of macrocyclic polyaminocarboxylate chelating agents which can be used for the stable attachment of radiometals to biological molecules such as proteins and antibodies. The conjugated chelates can be used for diagnostic and therapeutic applications.

2. Description of the Related Art

Macrocyclic polyaminocarboxylates such as 1,4,7,10-tetraazacyclododecane N,N',N",N'"-tetraacetic acid (DOTA) and 1,4,8,11-tetraazacyclotetradecane N,N'N",N'"-tetraacetic acid (TETA) are known to bind metals very tightly. ##STR1## DOTA and TETA were first prepared by J.F. Desreux (Inorg. Chem. 19:1319, 1980), by alkylation of 1,4,7,10-tetraazacyclododecane 1 and 1,4,8,11-tetraazacyclotetradecane 2 respectively with chloroacetic acid in base followed by acidification which sometimes precipitates the crude product. The crude product was further purified on cation exchange resin.

U.S. Pat. Nos. 5,132,409, 5,049,667, 4,923,985, 4,678,667 and 4,639,365 describe the synthesis of derivatives of 1,4,7,10-tetraazacyclododecane 1 and 1,4,8,11-tetraazacyclotetradecane 2 which are converted to the corresponding derivatives of DOTA and TETA using haloacetic acid with methods similar to that of Desreux, Id.

The ability of DOTA and TETA to tightly bind metals is advantageously used in contrast agents for magnetic resonance imaging, e.g. gadolinium-DOTA described by Magerstadt et al., Mag. Res. in Med. 3:808-812 (1986), and for the formation of stable radiometal labeled antibodies for diagnosis and/or therapy as described by Meares et al., Br. J. Cancer 62:21-26 (1990). For chemical attachment to antibody, DOTA and TETA must be suitably functionalized. In order to attach DOTA and TETA to antibodies these ligands must be derivatized with a group which can react with a group on the antibody such as an amine or sulfhydryl group. Several lengthy synthetic routes have been proposed to functionalize the carbon backbone of DOTA and TETA. ##STR2##

A para-bromoacetamidobenzyl derivative of TETA 3 was prepared by M. K. Moi et al., Anal,. Biochem. 148: 249-253 (1985) and U.S. Pat. No. 4,678,667 utilizing a low yield (about 12%) cyclization reaction. The para-bromoacetamidobenzyl derivative of DOTA 4 was also prepared by M. K. Moi et al., J. Am. Chem. Soc. 110: 6266-6267 (1988) and U.S. Pat. No. 4,678,667 using a higher yield intramolecular cyclization reaction. Compounds 3 and 4 were conjugated to antibodies via 2-iminothiolane as described by M. J. McCall et al., Bioconjugate Chem. 1: 222-226 (1990). Para-isothiocyanato-benzyl-DOTA and -TETA derivatives, compounds 5 and 6 were prepared by a different route whose key cyclization step, utilized two acylation reactions under high dilution conditions as described by O. A. Gansow, Nucl. Med. Biol. 18: 369-381 (1991) and U.S. Pat. No. 4,923,985. Compounds 5 and 6 did not require treatment of the antibody with 2-iminothiolane for conjugation.

Another functionalized DOTA, 1-n-butylamino-DOTA, was prepared by Cox et al., J. Chem. Soc. Chem. Commun. 1989: 797-798 (1989). The key step in this route was a Richman Atkins cyclization. This compound was then further functionalized by reacting with the p-nitrophenyl ester of 2-vinyl-6-(4'-carboxy-3'-oxa-butyl)pyridine to give 7 which could then be attached to antibodies using 2-iminothiolane. ##STR3##

All the methods listed above for the preparation of functionalized DOTA or TETA require long multi-step syntheses containing difficult cyclization steps. Others have investigated shorter routes which start with the commercial macrocycles 1,4,7,10-tetraazadodecane 1 or 1,4,8,11-tetraazacyclotetradecane 2. For example, a route to 8 which leaves one nitrogen available for further functionalization has been described by Dischino et al., Inorg. Chem. 30: 1265-1269 (1991). The Dischino et al. method is similar to that of Desreux, Inorg. Chem. 19: 1319 (1980) discussed above, involves the alkylation of commercially available 1,4,7,10-tetraazacyclododecane 1 with chloroacetic acid and requires anion exchange purification. The synthesis of 9 which is DOTA functionalized on a carbon alpha to one of the carboxylates is described by Kline et al., Bioconj. Chem. 2: 26-31 (1991). The key step in the Kline et al. synthesis is the alkylation of 1 to give 10. The non-alkylated amine is then further functionalized to give 9.

A simpler method of functionalizing DOTA which sacrifices one of the carboxylates is to form the mixed anhydride with isobutylchloroformate to give 11. Polylysine-DOTA (Sieving et al., Bioconj. Chem.. 1:65, 1990) and biotin-DOTA (Wu et al., Nucl. Med. Biol. 19:239, 1992) have been prepared by this method. A drawback of this method is that mixed anhydrides are very prone to hydrolysis and therefore these preparations cannot be stored for any length of time. ##STR4##

Previously described methods for the synthesis of DOTA and TETA have the disadvantages of requiring the use of haloacetic acid and require purification of the product by ion exchange. Other methods involve lengthy multi-step syntheses and difficult cyclization reactions and some yield unstable mixed anhydride product. Therefore, it would be highly desirable to provide a simple, high yield synthetic method for DOTA and TETA which can be coupled with a simple but effective functionalization reaction.

Furthermore, conjugation of DOTA and TETA chelates to antibody may be adversely affected by crosslinking. Crosslinking occurs when two or more active esters or mixed anhydrides are formed on each ligand and each active ester group/mixed anhydride reacts with a different antibody, thereby ,crosslinking the two antibodies. Crosslinking of antibodies produces dimers and oligomers which increases the molecular weight of the conjugate and results in an increase in non-target liver uptake of the labeled preparation. This can occur with the active ester or mixed anhydride methods since both are formed from the tetraacids. The key in these is to limit the formation of ester or mixed anhydride to one group per molecule. This is usually done by using excess DOTA or TETA when making the active ester or mixed anhydride. But since mixed anhydrides are readily hydrolyzed (split by the addition of water), and since a biological compound being conjugated is usually in water, water competes with the group being conjugated. Therefore, anhydrides are not very efficient. This disadvantage is shared by some of the prior art conjugation methods described above and also by the DTPA dianhydride method. Therefore it would be desirable to synthesize DOTA and TETA derivatized in a manner which allows chemical attachment to antibody with no cross-linking and gives immunoconjugates that have good serum stability and that produce good tissue distribution in vivo.

SUMMARY OF THE INVENTION

Accordingly, the invention provides a method for the synthesis of 1,4,7,10-tetraazacyclododecane N,N',N",N'"-tetraacetic acid (DOTA) and 1,4,8,11-tetraazacyclotetradecane N,N',N",N'"-tetraacetic acid (TETA) (Formula I). For this purpose 1,4,7,10-tetraazacyclododecane and 1,4,8,11-tetraazacyclotetradecane (Formula II) are provided and cyanomethylated using acid, formaldehyde, and cyanide compound yielding a tetranitrile (Formula III) which precipitates upon the addition of base.. The tetranitrile (Formula III) is hydrolyzed followed by acidification, evaporation to dryness, reconstitution and precipitation to give DOTA or TETA. ##STR5##

The advantages of this route of DOTA/TETA synthesis over existing routes are 1) its simplicity; 2) reactions proceed in high yield; 3) no purification by chromatography is needed.

The DOTA or TETA thus synthesized may be functionalized by the reaction of excess DOTA/TETA with N-hydroxysuccinimide and dicyclohexyl carbodiimide so that statistically one carboxy group is derivatized as an activated ester.

The functionalized DOTA or TETA may be conjugated to antibody by attachment through the activated ester site on the functionalized DOTA or TETA.

When chelated with radiometals, the compounds may be used for therapeutic applications and diagnostic applications such as SPECT and PET imaging. Radioimmunoconjugates of the present invention show good tumor uptake with lower non-specific uptake of radioactivity in bone, liver, kidney and other normal tissues.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1a and 1b are bar graphs illustrating tissue distribution of immunoconjugates in vivo;

FIGS. 2a and 2b are bar graphs showing additional comparative data.

DETAILED DESCRIPTION OF THE INVENTION

The invention is a method for a general synthesis of macrocyclic polyaminocarboxylate metal chelating agents for the stable attachment of radiometals to biological molecules including proteins and antibodies for diagnostic as well as therapeutic applications. The chelating agents prepared by this method include high yields of 1,4,7,10-tetraazacyclododecane N,N',N"N'"-tetraacetic acid (DOTA) and 1,4,8,11-tetraazacyclotetradecane N,N',N",N'"-tetraacetic acid (TETA)

These chelating agents may be synthesized, derivatized, conjugated to antibodies and/or used to chelate radiometals.

The synthesis is illustrated in Scheme 1: ##STR6##

Commercial macrocycles 1, and 2 are cyanomethylated using acid such as sulfuric acid, formaldehyde and cyanide compound such as potassium cyanide or sodium cyanide to give cyanonitriles 3 and 4. 3 and 4 are hydrolyzed using base such as lithium hydroxide followed by acidification with acid such as HCl, evaporation to dryness, reconstitution in alcohol, e.g., methanol and precipitation, e.g., with acetone give DOTA and TETA respectively. The DOTA and TETA may be used to chelate metals, particularly radiometals.

Temperature, time and molar ratios of reactants in the two steps depicted in Scheme I are not critical and may be easily determined by the skilled artisan. For purposes of economy and efficiency, the reaction of the first step is carried out under temperature conditions which take into .account the heat of hydration. The time of the first step may be judged by the presence of precipitate and may be, for example, from about 24 to about 48 hours. The formaldehyde and cyanide compound are provided in excess of the amount of cyclams 1 and 2, preferable in a molar ratio of at least four moles each of formaldehyde and cyanide compound per mole of cyclam. The molar ratio of acid in the first step is preferably about two moles per mole of cyclam.

Likewise in the second step hydrolysis, temperature, time and molar ratios of reactants are not critical. A temperature for reflux conditions is utilized, e.g. about 80° C. to about 90° C. The reaction may be followed by NMR to completion, for example, to about two days. The base is provided in a molar ratio of at least four moles base per mole of cyclam. Sufficient acid is used to bring the pH to an acid range, preferably to about pH 1-3.

The chelating agents may be derivatized by converting an average of one carboxylic acid on the chelate to an activated ester which is capable of reacting with either an amine or a sulfhydryl group on a biological binding agent. The derivatization is Shown in Scheme 2: ##STR7## DCC=dicyclohexylcarbodiimide

NHS=N-hydroxysuccinimide

DMSO=dimethylsulfoxide

DCU=dicyclohexyl urea

Derivatization of a carboxylic acid resulting in ester formation at the carboxylic acid site may be achieved using, for example, one molar equivalent of DOTA or TETA and 0.5 equivalent dicyclohexylcarbodiimide and N-hydroxysuccinimide in a solvent such as dimethyl sulfoxide (DMSO). This solution may be stored for extended periods of time, e.g. up to two months at or more 0° C., without loss of reactivity.

The ligands, i.e., the chelating agents, may be conjugated to biological binding agents. Biological binding agents to which the chelating agents may be conjugated include substances capable of localizing in vitro or in vivo to a tumor or neoplasia. Neoplasia may occur, for example, in animals such as mammals including humans. Neoplasia is progressive, uncontrolled cell division which, if progeny cells remain localized, at least initially, results in the formation of an abnormal growth called a tumor or neoplasm. A neoplasm may be malignant or benign. A malignant neoplasm invades adjacent tissues and may metastasize. A neoplastic growth is generally considered to be a non-inflammatory mass formed by the growth of new cells and having no physiologic function. The conjugated radiometal chelates of the invention can be formulated per se in pharmaceutical preparation or formulated in the form of pharmaceutically acceptable salts. These preparations can be prepared according to conventional chemical methods. Anti-tumor agents such as cis-platin or bleomycin have been used therapeutically in humans to interfere with rapid cell division which occurs in neoplasia. Radionuclides have also been used for the detection and/or selective destruction of tumors localized through the use of monoclonal antibodies.

Therefore, the derivatized macrocyclic polyaminocarboxylate metal chelating agents may be conjugated with various biological binding agents for localizing to the desired area. The biological binding agents may include antibodies (polycolonal and monoclonal), antibody fragments, e g the F(ab')2, Fab', or Fc portions of an immunoglobulin Ig, other proteins, protein fragments or peptides, genetically engineered proteins, peptides and antibodies, single chain antibodies, small molecular recognition units, polysaccharides, nucleic acids, steroids, enzymes, drugs, vitamins, and a number of other biologically active compounds.

The method of the invention was found to be superior to common methods previously used in the art for labeling antibody using other functionalized polyaminocarboxylates such as diethylenetriamine pentaacetic acid (DTPA) anhydride (Hnatowich et al., Science 220:613, 1983). Radiometals can be complexed with the chelating agent-biological binding agent conjugates.

Based on various criteria such as imaging photons, particle emission, dosimetry, and feasibility of production, a number of radiometals are considered suitable for labeling antibodies for radioimmunoimaging (RII) and/or radioimmunotherapy (RIT) (Mausner and Srivastava, Med. Phys. 1993, in press). Examples of suitable radiometals are: 55 Co, 64 Cu, 66 Ga, 68 Ga, 97 Ru, 99m Tc, 111 In, and 203 Pb for imaging, and 47 Sc, 67 Cu, 90 Y, 105 Rh, 109 Pd, 153 Sm, 177 Lu, 188 Re, 199 Au, and 212 Bi for radiotherapy. While the chelating agents of this invention will produce more stable complexes with most above radiometals, 55 Co, 64 Cu, 67 Cu, 111 In, 203 Pb, 90 Y, and 153 Sm would benefit most because of their coordination geometries,, and because they require bifunctional chelating agents which bind the radiometal with a higher denticity (number of coordination sites) and/or incorporate greater structural rigidity, in order to produce immunoconjugates with better in-vivo kinetic stability.

Although some radiometals have been shown to produce good biodistribution using modified polyaminocarboxylates, e.g. DTPA functionalized at the carbon backbone (Harrison, et. al., Nucl. Med. Biol. 18:469, 1991; Gansow, Nucl. Med. Biol. 18:369, 1991) non-specific uptake of radioactivity has been undesirably high in bone and kidney with 203 Pb and in bone and liver with 90 Y.

Biodistribution studies showed that Y, Pb and Cu-DOTA chelates conjugated with antibody had better biodistribution than CTTHA (N,N'-(2-aminoethyl )-trans-1,2-diaminocyclohexane-N,N',N",N",N'",N'"-hexaacetic acid), CDTPA (cyclohexyl diethylenetriamine-pentaacetic acid or N-(2-aminoethyl)-trans 1,2 -diamino cyclohexane-N,N', N',N",N", pentaacetic acid), 4-ICE (4-isothiocyanato-trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid), CDTAMA (trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid monoanhydride), and DTPADA (the bicyclic anhydride of DTPA) (control). The cyclohexyl ligands CTTHA, CDTPA, 4-ICE, and CDTAMA are described in U.S. Pat. Nos. 5,021,571 and 5,089,663. Synthesis of 4-ICE is described in U.S. patent application Ser. No. 867,533 filed Apr. 13, 1992.

As non-limiting examples, two antibody systems were investigated: anticolon carcinoma MAb 17-1A (whole IgG and F(ab')2 fragment) and an anti-CEA F(ab')2 preparation. The average number of ligands per MAb varied between 1 and 3. In a typical case, contacting a 60/1 molar ratio of activated ligand/17-1A IgG in 0.1M NaHCO3 at room temperature for two hours yielded 2-3 ligands/MAb with negligible cross-linking (1% by HPLC). 88 Y, 67 Cu and 203 Pb labeled DOTA-17-1A and 67 Cu-TETA-17-1A were stable in serum (1-4% loss after 4 days).

Biodistribution studies were performed in human tumor xenografted nude mice. As an example, 88 Y-17-1A immunoconjugates showed progressive improvement as follows: DOTA≧CTTHA≧CDTPA>4ICE>>CDTAMA>>DTPADA. Based on these and similar data, it can be concluded that both denticity and the rigidity of the bifunctional chelating agent are important factors that contribute to higher in-vivo stability of many radiometal immunoconjugates, especially those of Cu, Pb, Y, and other rare earths. Monofunctionalized DOTA, a rigid ligand with 7 coordination sites, appears to provide the best combination of the ligands studied above.

The chelates of the invention may also be used in Emission Tomography to measure physiological function of organs and related biochemical processes in both health and disease. The two modes of emission tomography are single-photon emission computed tomography (SPECT) and positron emission tomography (PET). SPECT uses radionuclides that emit a single photon of a given energy and these include gamma ray emitters such as 67 Ga, 97 Ru, 99m Tc, 111 In, 123 I, 131 I, 203 Pb, and others. PET uses radionuclides known as positron emitters such as 11 C, 15 O, 18 F, 55 Co, 64 Cu, 68 Ga, 75 Br, 89 Zr, 124 I, and others for coincidence detection in which the positron and electron annihilate each other to form two photons at 180° angle from each other. In SPECT and PET, transverse section reconstruction of the radionuclide distribution within the body is obtained by acquiring images of multiple slices of the organ or the whole body. The chelates of the invention can be used for SPECT and PET imaging studies of the physiology, function, and biochemistry of tumors, and other organs and tissues.

The invention is illustrated by the following non-limiting examples.

EXAMPLE 1

Synthesis of N,N',N",N'"-Tetracyanomethylene-1,4,7,10-tetraazacyclododecane

A solution of 3.0 g (9.4 mmol) 1,4,7,10-tetraazacyclododecane tetrahydrochloride in 10 ml H2 O was stirred and cooled to 0°-2° C. To this was slowly added 1.05 ml (18.8 mmol) concentrated H2 SO4 followed by 3.52 ml of 37% formaldehyde. Over a period of one hour a solution consisting of 2.7g (41 mmol) potassium cyanide dissolved in 15° ml H2 O was added. The reaction was then allowed to warm to room temperature and stirred for 24 H. During this time a white precipitate formed. The reaction was then made basic (pH≈10) by the addition of 3M NaOH. As the mixture was neutralized the precipitate dissolved and reprecipitated when the pH was greater than 8. The solid was collected, washed with H2 O, dried under vacuum and recrystallized from a mixture of ethylacetate/acetone to give two crops of a white solid totaling 2.9 g (92%) mp 157°-159° C.

IR (mineral oil) 2210 cm-1 NMR (60 MHz)(CD3)2 SO and CDCl3 with 1% TMS δ2.60 (s,16H) δ3.67 (s,8H) Elemental Analysis Calc: C, 58.52; H, 7.37; N, 34.12; Found: C, 58.56; H, 7.38; N, 34.05; ##STR8##

EXAMPLE 2

Synthesis of 1,4,7,10-Tetraazacyclododecane-N,N',N",N'"-tetraacetic acid

To a solution of 2.5 g (7.7 mmol) N,N',N",N'"-tetracyanomethylene-1,4,7,10-tetraazacyclododecane as prepared in Example 1 and dissolved in 30 ml methanol was added 150 water and 3.9 g (93 mmol) lithium hydroxide monohydrate. This :solution was allowed to gently reflux in an open 500 ml round bottom flask for two days. Water was added as needed to maintain the solution level at 100 ml. The reaction was cooled to room temperature, acidified to pH 2 by the addition of 3M HCl, and concentrated to a sticky residue. The residue was dried by the addition of methanol followed by concentration to dryness. This was repeated twice more. The dry powdery residue was dissolved in 30 ml MeOH and added dropwise to a stirred solution of 300 ml acetone. The precipitated product was collected, washed with acetone, and dried under vacuum to give 3.4 g (92%) of a white solid.

IR (mineral Oil) 1.710 cm-1, 1630 cm-1 NMR (60 MHz)D2 O+NaOD, pH˜14) δ3.07 (s,8), 2.63 (s,16) ##STR9##

EXAMPLE 3

Synthesis of N,N',N",N'"-Tetracyanomethylene-1,4,8,11-tetraazacyclotetradecane

To a solution of 8.33 ml concentrated HCl in 20 ml H2 O was added 5.0 g (25 mmol) cyclam. This solution was stirred and cooled to 0°-2° C. in an ice bath. To this solution was added slowly 2.8 ml concentrated H2 SO4 followed by 9.4 ml 37% formaldehyde. Next, a solution consisting of 7.2 g (110 mmol) potassium cyanide dissolved in 20 ml H2 O was added over a period of one hour. The reaction was allowed to warm to room temperature and stirred for 24 H. During this time a white precipitate formed. The reaction mixture was then made basic (pH 10) by the addition of 3M NaOH. As the mixture was neutralized the solid in the reaction dissolved and reprecipitated when the pH was greater than 8. The solid was collected, washed with H2 O, dried under vacuum to give 8.3 g (94%) of a white solid. The filtrate was extracted with CH2 Cl2 and the CH2 Cl2 extracts combined, dried with MgSO4 and concentrated to give 0.4 g (4%) of an off white solid. The solids were combined and recrystallized from ethylacetate/acetone to give 3 crops of crystals totaling 8.18 g (92%). mp 170°-172° C.

IR mineral oil 2210 cm-1 NMR (60 MHz)(CD3)2 SO+CDCl3 +1% TMS δ3.67 (s,8), 2.5 (s,16), 1.8-1.3 (m,4) Elemental Analysis Calc: C, 60.65; H, 7.92; N, 31.43; Found: C, 60.65; H, 7.98; N, 31.36; ##STR10##

EXAMPLE 4

Synthesis of 1,4,8,11-Tetraazacyclotetradecane-N,N',N",N'"-tetraacetic acid

To a solution of 7 0 g N,N',N",N'"-tetracyanomethylene-1,4,8,11-tetraazacyclotetradecane (19.7 mmol) as prepared in Example 3 and dissolved in 40 ml methanol was added 200 ml H2 O and 9.9 g lithium hydroxide monohydrate (236 mmol). This solution was allowed to reflux gently in an open 500 ml round bottom flask for two days. Water was added as needed to keep the solution level at approximately 150 ml. The reaction was cooled to room temperature, acidified to pH 2 by the addition of 3M HCl and evaporated to a sticky solid. The solid was dried by being dissolved in methanol and again evaporated to dryness. Additional methanol was added and the solution evaporated to dryness. This was repeated a third time. The residue was dissolved in 40 ml methanol and added dropwise to a stirred solution of acetone (400 ml). The precipitated product was collected, washed with acetone, and dried under vacuum to give 7.9 g (91%).

IR (mineral oil) 1635 cm-1 NMR (60 MHz )(D2 O+NaOD) δ1.97-1.33 (m,4), 2.63 (s,16), 3.07 (s,8) ##STR11##

Examples 1-4 show that the method of the invention is simple, efficient, and results in high product yield of over 90%.

EXAMPLE 5

The serum stability of radiometal conjugates of DOTA and TETA was determined and the data are summarized in Table 1. Additional data using other ligands DTPADA and 4-ICE are included for comparison.

              TABLE 1______________________________________Serum Stability of Radiometal Conjugates               Radioactivity with               Conjugate (HPLC)Radiometal   Conjugate         1D       4D______________________________________Lead-203   Anti-CEA-F(ab').sub.2 -DOTA                     100      100   Anti-CEA-F(ab').sub.2 -4-ICE                     71        5Yttrium-88   17-1A-IgG-DOTA    98       96   17-1A-IgG-DTPADA  57       15   17-1A-IgG-4-ICE   48       14Copper-67   17-1A-IgG-DOTA    99       96-99   17-1A-IgG-TETA    97       98   17-1A-IgG-DTPADA  57       15   17-1A-IgG-4-ICE   48       14______________________________________
EXAMPLES 6-27

Immunoconjugates of Lead-203 and Yyttrium-88

The following polyaminocarboxylates (PACS) were evaluated and compared: (1) cyclohexyl EDTA monoanhydride (CDTAMA); (ii) 4-isothiocyanato-cyclohexyl EDTA (4-ICE); (iii) cyclohexyl DTPA (CDTPA); (iv) cyclohexyl TTHA (CTTHA); and (v) 1,4,7,10-tetraazacyclododecane N,N', N",N'"-tetraacetic acid (DOTA). Cyclohexyl PACS were synthesized and functionalized using procedures described in U.S. Pat. Nos. 5,021,571 and 5,089,663. Conjugation to MAb was done .either through a monofunctionalized derivative (CDTAMA, CDTPA-NHS, CTTHA-NHS) or through the 4-SCN group (4-ICE). DOTA was synthesized using the new procedure utilizing cyanomethylation of commercial 1,4,7,10-tetraazacyclododecane followed by hydrolysis (Scheme 1) and conjugated to MAb through one of the carboxylates that was converted to an NHS ester (R. G. Buckley and F. Searle, FEBS 166:202, 1984). DTPADA was used as a control ligand in all experiments.

Two antibody systems were investigated: anticolon carcinoma MAb 17-1A (Y and Pb) and an anti-CEA F(ab')2 preparation (Pb only). The average number of ligands per MAb varied between 1 and 3. Lead-203 was obtained from Nordion International as a solution in HCl (sp. act. 1.0 mCi/μg), and no-carrier-added 88 Y (used as a stand-in for 90 Y for convenience) from Los Alamos National Laboratory. Centricon-purified immunoconjugates were labeled with Pb and Y at pH 5-6 (acetate or citrate buffers) and then purified further by size-exclusion HPLC. Labeling yields for the various preparations ranged between 40 and 80% (except -10% for Pb-DOTA, Y-CDTPA, and Y-CTTHA). Serum stability was determined from in-vitro incubations for up to 5 d. Biodistribution studies were performed in human tumor xenografted nude mice. The results are shown in Table 2 below and in FIGS. 1a, 1b, 2a and 2b.

Table 2 shows tissue distribution of 203 Pb immunoconjugates in mice at 24 hours and 96 hours (Examples 6-15).

FIGS. 1a and 1b show tissue distribution of 88 Y-17-1A immunoconjugates in SW-948 human colon carcinoma xenografted nude mice at 24 hours (left) and 96 hours (right) (Examples 18-27). 111 In-4-ICE-17-1A data are included for comparison (Examples 16 and 17).

FIGS. 2a and 2b show tumor to organ ratios of 88 Y-17-1A IgG in Mice at 24 hours (left) and 96 hours (right) (Examples 18, 19,, 20, 21, 26 and 27).

Ligand abbreviations in these data are explained in the text.

                                  TABLE 2__________________________________________________________________________Tissue Distribution of .sup.203 Pb Immunoconjugates in Nude Tumor mice*       Time,                            WholeEx.   Conjugate**       Hr  Tumor Blood Liver                            Kidney                                  Bone  (% Dose)__________________________________________________________________________ 6 .sup.203 Pb Nitrate       24  0.4 ± 0.2                 7.7 ± 1.5                       6.0 ± 0.5                            27.6 ± 1.0                                  12.1 ± 0.7                                        58   (control)    --     (0.05)                        (0.07)                             (0.01)                                   (0.03) 7          48  0.4 ± 0.2                 1.8 ± 0.3                       3.3 ± 0.7                            15.2 ± 1.7                                  13.3 ± 1.1                                        61           --     (0.22)                        (0.12)                             (0.03)                                   (0.03) 8 DTPA-DA-17-1A       24  1.1 ± 0.2                 3.6 ± 0.1                       5.3 ± 0.2                            18.6 ± 4.3                                  13.0 ± 1.6                                        61   (10%, 1d)    --    (0.3) (0.2)                             (0.06)                                   (0.08) 9          96  0.4 ± 0.1                 0.9 ± 0.1                       2.7 ± 0.4                            6.3 ±  1.5                                  8.1 ± 0.3                                        35           --    (0.4)  (0.15)                             (0.06)                                   (0.05)10 CDTA-MA-17-1A       24  6.1 ± 0.2                 8.6 ± 0.9                       6.4 ± 0.7                            16.5 ± 0.7                                  12.1 ± 0.4                                        77   (50%, 1d)    --    (0.7) (1.0)                            (0.4) (0.5)11          96  1.1 ± 1.1                 1.3 ± 0.3                       2.2 ± 0.3                            6.5 ± 0.2                                  14.1 ± 1.5                                        48           --    (0.9) (0.5)                            (0.2)  (0.08)12 4-ICE-CEA       24  7.7 ± 1.2                 4.7 ± 0.7                       8.5 ± 0.9                            19.1 ± 2.2                                  7.6 ± 0.7                                        76   F(ab').sub.2 --    (1.6) (0.9)                            (0.4) (1.0)   (71%, 1d)13          96  2.3 ± 0.5                 1.6 ± 0.2                       3.0 ± 0.4                            8.1 ± 0.8                                  11.0 ± 1.3                                        46           --    (1.5) (0.8)                            (0.3) (0.2)14 DOTA-CEA 24  19.3 ± 4.6                 3.1 ± 0.6                       9.8 ± 1.5                            30.0 ± 5.0                                  1.6 ± 0.2                                        94   F(ab').sub.2 --    (6.3) (2.0)                            (0.6) (12)   (100%, 5d)15          96  12.2 ± 2.1                 0.14 ± 0.01                       3.7 ± 0.4                            14.9 ± 1.0                                  1.0 ± 0.1                                        48           --    (87)  (3.3)                            (0.8) (12)__________________________________________________________________________ *Data (% dose per g) are average of 3-10 animals ± 1 std. deviation. Tumor to tissue ratios are included in parentheses. All preparations were HPLC purified and monomeric fractions were injected i.v. into the mice. S 948 colon carcinoma xenografts were used for 171A experiments and LS174T xenografts for the antiCEA experiments. **Ligand abbreviations are explained in the text. Invitro serum stability at 37° C. shown in parentheses under the conjugate.

The results show that in the case of 203 Pb immunoconjugates with 17-1A IgG (Table 1), CDTAMA produced higher blood and whole body levels and increased tumor uptake compared to DTPADA. Bone and kidney uptake, however, remained high. In the CEA-F(ab')2 system, the rigid DOTA gave higher tumor to non-tumor ratios (Table 1) compared with the semi-rigid 4-ICE (T/blood, T/liver, T/bone, T/kidney at 96 hr: 87 vs 1.5; 3.3 vs 0.8; 12.0 vs 1.3; 0.8 vs 0.3, respectively). Biodistribution studies with 88 Y-17-1A immunoconjugates (FIGS. 1 and 2) showed progressive improvement as follows: DOTA≧CTTHA≧CDTPA>4ICE>>CDTAMA>>DTPADA.

These results also demonstrate that common methods for labeling MAb using functionalized polyaminocarboxylates, such as the DTPA dianhydride (DTPADA) and others, are not ideal for use with 203 Pb and 90 Y. These radiometals share a common feature in that they require bifunctional chelating agents with a higher denticity (number of coordination sites) and greater structural rigidity in order to obtain immunoconjugates with better in-vivo kinetic stability. Although some radiometals produce improved biodistribution using DTPA functionalized at the carbon backbone (A. Harrison et al., Nucl. Med. Biol. 18:469 (1991); O. A. Gansow, Nucl. Med. Biol. 18:369 (1991)) , non-specific uptake of radioactivity is still undesirably high in bone and kidney with 203 Pb and in bone and liver with 90 Y.

Based on these data, it is concluded that both denticity and the rigidity of the bifunctional chelating agent are important factors that contribute to higher in-vivo stability of Y and Pb radioimmunoconjugates (Tables 3-5). Monofunctionalized DOTA, a rigid ligand with 7 coordination sites appears to provide the best combination and warrants further investigation for use with 203 Pb and 90 Y.

                                  TABLE 3__________________________________________________________________________Effect of denticity (coordination sites) and structural rigidity of theligandon the 96 hr biodistribution of .sup.203 Pb and .sup.88 Yimmunoconjugates in nude tumor mice*                .sup.203 pb                         .sup.88 YImmunoconjugate     Denticity          Rigidity                T**                   T/L                      T/B                         T**                            T/L                               T/B__________________________________________________________________________DTPADA-17-1A     7    No    0.40                   0.15                      0.05                         3.6                            0.32                               0.34CDTAMA-17-1A     5    Semi-rigid                1.1                   0.50                      0.08                         -- -- --4-ICE-17-1A     6    Semi-rigid                -- -- -- 6.4                            1.4                               0.484-ICE-CEA-F(ab').sub.2     6    Semi-rigid                2.3                   0.80                      0.20                         -- -- --CDTPA-NHS-17-1A     7    Semi-rigid                -- -- -- 11.4                            1.3                               1.7CTTRA-NHS-17-1A     9    Semi-rigid                -- -- -- 10.8                            1.9                               1.5DOTA-NHS-17-1A     7    Rigid -- -- -- 13.5                            2.4                               2.6DOTA-CEA-F(ab').sub.2     7    Rigid 12.2                   3.3                      12 -- -- --__________________________________________________________________________ *Data shown are average of 3-10 mice per experiment. Ttumor; Bbone; Lliver. Ligand abbreviations are explained in the text. Other experimenta details same as in Table 1. **Tumor uptake in % injected dose per g.

              TABLE 4______________________________________Improvement in Tumor/Organ Ratiosof .sup.203 Pb ImmunoconjugatesDOTA-NHS vs. 4-ICE*                            ImprovementRatio,  Time                     Factortumor to:   (Hr)   4-ICE    DOTA-NHS DOTA-NHS/4-ICE______________________________________Blood   24     1.6      6.3      3.9   96     1.5      87       58Liver   24     0.9      2.0      2.2   96     0.8      3.3      4.1Kidney  24     0.4      0.6      1.5   96     0.3      0.8      2.7Bone    24     1.0      12       12   96     0.2      12       60% dose per   24     7.7      19.3     2.5g in tumor   96     2.3      12.2     5.3______________________________________ *Data using AntiCEA-F(ab').sub.2 antibody; LS174T tumor xenografts in nud mice.

              TABLE 5______________________________________Improvement in Tumor/Organ Ratios.sup.88 Y ImmunoconjugatesDOTA-NHS vs. DTPA*                            ImprovementRatio,  Time                     Factortumor to:   (Hr)   4-ICE    DOTA-NHS DOTA-NHS/4-ICE______________________________________Blood   24     0.8      0.8      1.0   96     2.2      1.9      0.9Liver   24     0.3      1.7      5.7   96     0.3      3.3      11Kidney  24     1.5      3.7      2.5   96     1.5      6.2      4.1Bone    24     0.5      2.8      5.6   96     0. 3     3.5      11.7dose per   24     5.2      11.0     2.1g in tumor   96     3.5      10.0     2.9______________________________________ *Data using anticolon ca Mab 171A; SW948 tumor xenografts in nude mice
EXAMPLES 28-56

Immunoconjugates of Copper-64, Copper-67, and Samarium-153

Whole IgG or F(ab')2 fragments of anticolon carcinoma antibody 17-1A were conjugated with the macrocyclic ligands 1,4,7,10-tetraazacyclododecane N,N',N",N'"tetraacetic acid (DOTA, synthesis described in scheme 1); 1,4,8,11-tetraazacyclotetradecane N,N',N",N'"tetraacetic acid (TETA, synthesis described in scheme 2), and with DTPA, 4-ICE, CDTPA, and CTTHA using either a monofunctionalized derivative (CDTPA-NHS, CTTHA-NHS), through the 4-SCN group (4-ICE), or the dianhydride (DTPA). DOTA and TETA were conjugated to MAb through one of the carboxylates that was converted to an NHS ester (Buckley et al., FEBS 166:202, 1984). Radiolabeling with copper was carried out by incubating the 67 Cu or 64 Cu chloride solution in 0.05N HCl with the conjugates in 0.1M sodium bicarbonate, pH 8.4 buffer, with 0.1M acetate as the weakly chelating buffer system. Purification was carried out by HPLC using a Zorbax-GF250 sizing column and 0.1M, pH 7.0 phosphate buffer as the eluent. EDTA (10 μl of a 0.05M solution) was used to remove unbound and/or non-specifically bound radioactivity. Labeling efficiencies were 80-90% for all conjugates and immunoreactivity retention ranged between 60-90%, as determined from live cell-binding assays using SW-948 human colon carcinoma cells.

Serum stability studies were performed to determine the relative efficiency of the various ligands for chelating copper. The labeled conjugates were incubated in mouse serum at 37° C. for up to 5 d. Aliquots were removed and injected onto a Zorbax GF-250 HPLC column and eluted with 0.1M phosphate buffer, pH 7.0, at a flow rate of 1 ml/min. Fractions (6 drops each) were collected and counted for radioactivity using a gamma counter. The percent of injected activity that eluted with the antibody was determined. DOTA and TETA conjugates showed 90-95% stability after 96 h whereas 4-ICE conjugate retained only 39% MAb-bound activity, after 24 hours. All conjugates retained 95-99% of the copper as MAb-bound activity when incubated in saline only, for up to 96 hours.

Biodistribution of 67 Cu and 64 Cu labelled conjugates of 17-1A (IgG and F(ab')2) was determined in normal (Balb/c) mice as well as human colon carcinoma (SW 948 cells) xenografted nude mice. Representative data are summarized in Tables 6 and 7. Four to five animals were used per time point for each radiolabelled preparation. The animals were sacrificed at 24 and 96 h (or other time periods) following the i.v. administration of the various immunoconjugates.. In-vivo stability in normal mice was in the order DOTA≈TETA>>4-ICE (Table 6). As expected, F(ab)'2 conjugates cleared faster from blood than IgG conjugates. Results in tumor-bearing nude mice are summarized in Table 6 along with tumor to normal tissue ratios. DOTA conjugates gave higher tumor uptakes than the TETA conjugates. The 67 Cu-IgG-DOTA conjugate yielded the highest tumor uptake at 96 h and thus the tumor to organ ratios were higher than with other conjugates. F(ab)'2 conjugates again, as expected, cleared faster than the whole IgG conjugates. Results with 64 Cu for all the conjugates were generally similar to those with 67 Cu.

                                  TABLE 6__________________________________________________________________________Biodistribution of .sup.67 Cu Labeled Anticolon Carcinoma MonoclonalAntibody 17-1A in Normal Mice.sup.a.                                Whole BodyEx.   Conjugate.sup.b         Time (h)              Blood Kidney                          Liver Retention.sup.c__________________________________________________________________________28 4-ICE-IgG  24   2.7 ± 0.4                    9.2 ± 0.7                           18 ± 0.4                                80 ± 329            96   1.2 ± 0.1                    7.1 ± 0.6                          10.3 ± 0.8                                50 ± 330 DOTA-1NHS-IgG         24   18.5 ± 1.9                    4.8 ± 0.3                          8.7 ± 0.4                                83 ± 631            96   12.9 ± 0.5                    4.2 ± 0.2                          7.0 ± 0.9                                68 ± 332 TETA-1NHS-IgG         24   15.4 ± 0.3                    5.4 ± 0.2                          7.7 ± 0.4                                88 ± 433            72   11.1 ± 1.1                    5.0 ± 0.4                          6.3 ± 0.5                                73 ± 434 4-ICE-F(ab').sub.2         24   1.7 ± 0.1                    6.2 ± 0.3                          11.8 ± 0.6                                56 ± 335            96   0.8 ± 0.1                    4.3 ± 0.4                          6.1 ± 0.5                                32 ± 336 DOTA-1NHS-F(ab').sub.2         24   8.0 ± 0.5                    7.0 ± 1.0                          8.3 ± 0.8                                83 ± 537            96   1.0 ± 0.1                    4.1 ± 0.2                          6.4 ± 0.4                                42 ± 238 TETA-1NHS-F(ab').sub.2         24   2.0 ± 0.1                    55.5 ± 2.9                          8.0 ± 0.3                                75 ± 139            96   0.5 ± 0.1                    18.3 ± 1.5                          4.6 ± 0.1                                35 ± 1__________________________________________________________________________ .sup.a % Injected dose/g; n = 5 .sup.b Whole IgG used except as indicated .sup.c % Injected dose remaining

                                  TABLE 7__________________________________________________________________________Biodistribution.sup.a of .sup.67 Cu Labeled Anticolon CarcinomaMonoclonal Antibody 17-1Ain Human Tumor (SW 948 cells) Xenografted Nude Mice.                                      Whole BodyEx.   Conjugate  Time (h)              Tumor Blood Kidney                                Liver Retention.sup.b__________________________________________________________________________40 DOTA-1NHS-IgG         24   11.2 ± 1.3                    15.5 ± 1.2                          1.4 ± 0.3                                9.4 ± 0.9                                      112 ± 7                    (0.7) (2.4) (1.2)41            96   13.5 ± 1.5                    10.6 ± 1.6                          4.9 ± 0.2                                7.0 ± 0.8                                      84 ± 6                    (1.3) (3.0) (2.1)42 DOTA-1-NHS-F(ab').sub.2         24   10.3 ± 2.2                    9.4 ± 0.6                          14.7 ± 0.7                                15.4 ± 0.7                                      122 ± 2                    (1.1) (0.7) (0.7)43            96   5.2 ± 0.4                    1.3 ± 0.2                          7.5 ± 0.6                                7.5 ± 0.6                                      57 ± 3                    (4.0) (0.7) (0.7)44 TETA-1-NHS-IgG         24   10.3 ± 0.7                    16.8 ± 1.0                          4.9 ± 0.3                                8.6 ±  0.7                                      103 ± 4                    (0.6) (2.1) (1.2)45            96   7.5 ± 1.2                    9.4 ± 0.7                          4.6 ± 0.2                                6.4 ± 0.3                                      74 ± 5                    (0.8) (1.6) (1.2)46 TETA-1-NHS-F(ab').sub.2         24   9.3 ± 2.4                    12.8 ± 0.6                          8.8 ± 0.3                                9.6 ± 0.4                                      99 ± 4                    (0.7) (1.1) (1.0)47            96   4.2 ± 1.6                    5.6 ± 0.4                          5.8 ± 0.6                                5.7 ± 0.4                                      56 ± 5                    (0.7) (0.7) (0.7)__________________________________________________________________________ .sup.a % Injected dose/g; n = 5. Tumor to tissue ratios shown in parentheses .sup.b % injected dose remaining

Labeling with 153 Sm was carried out as follows. A solution of 153 SmCl3 in 0.05N HCl was added to the conjugates in 0.1M bicarbonate, pH 8.3, and 0.15M acetate pH 6.0, and incubated at 37° C. overnight. The preparations were purified using either size exclusion HPLC or Centricon filtration, as described earlier for other radioconjugates. Percent labeling efficiencies for DOTA, CDTPA, CTTHA and 4-ICE were 100, 65, 5, and 94, respectively. TETA conjugates did not label under these conditions. Serum incubation experiments showed loss of label at 4 days as follows: DOTA, 45%; CDTPA, 64%; CTTHA, 72%; 4-ICE, 98%. Thus, although not as effective as for Cu, Sm-DOTA conjugates showed the highest stability among the ligands tested. Biodistribution results in human tumor xenografted nude mice (SW 948 anticolon carcinoma cells) showed considerably better tumor uptake of the DOTA conjugate compared to other ligands. The data are summarized in Table 8.

                                  TABLE 8__________________________________________________________________________Biodistribution.sup.a of .sup.153 Sm Labeled Anticolon CarcinomaMonoclonal Antibody 17-1A in HumanTumor (SW 948 cells) Xenografted Nude Mice.                                    Whole BodyEx.   Conjugate    Time (h)         Tumor              Blood Liver Kidney                               Bone (% Dose)__________________________________________________________________________48 DTPA  96   4.3 ± 0.5              2.8 ± 0.6                    8.6 ± 0.7                          1.8 ± 0.4                               3.4 ± 0.7                                    76 ± 349 CDTPA 24   1.9 ± 0.6              1.4 ± 0.2                    31.3 ± 7.6                          2.5 ± 0.5                               6.3 ± 1.3                                    90 ± 350       96   1.3 ± 0.3              0.13 ± 0.02                    26.1 ± 6.5                          1.8 ± 0.8                               7.2 ± 1.4                                    78 ± 751 CTTHA 24   3.5 ± 0.5              6.6 ± 0.5                    26.0 ± 8.3                          2.7 ± 0.2                               4.4 ± 0.6                                    92 ± 352       96   4.1 ± 0.4              2.6 ± 0.2                    25.9 ± 2.3                          1.9 ± 0.2                               5.9 ± 0.6                                    80 ± 553 4-ICE 24   3.5 ± 0.5               1.7 ± 0.08                    23.4 ± 1.6                          4.6 ± 0.7                               9.3 ± 0.4                                    80 ± 454       96   1.7 ± 0.2              0.04 ± 0.01                    17.4 ± 2.0                          2.6 ± 0.2                               9.9 ± 1.1                                    74 ± 255 DOTA  24   7.9 ± 1.1              12.2 ± 1.3                    13.7 ± 0.5                          4.8 ± 0.6                               5.0 ± 0.4                                    93 ± 5    96   9.6 ± 1.0              4.2 ± 0.5                    15.1 ± 1.1                          3.6 ± 0.2                               8.4 ± 0.5                                    81 ± 3__________________________________________________________________________ .sup.a % Injected dose per g; n = 5 .sup.b % Injected dose remaining

From these data, it is concluded that the 7-coordinate DOTA-NHS produces stable 64 Cu and 67 Cu immunoconjugates. Although results with 153 Sm are not as good the distribution of 153 Sm-DOTA is much better compared to the other polyaminocarboxylate ligands. Macrocylic or other ligands for 153 Sm need further improvement.

Claims (2)

What is claimed is:
1. A method of producing a compound of Formula I ##STR12## comprising the steps of a) providing a compound of Formula II ##STR13## b) cyanomethylating the compound of Formula II to yield a tetranitrile compound of Formula III ##STR14## c) hydrolyzing the compound of Formula III with lithium hydroxide followed by acidification with hydrochloric acid to form a hydrolysis product containing a compound of formula I
d) isolating the compound of formula I by
1) evaporating the hydrolysis product to dryness,
2) reconstituting the hydrolysis product in alcohol, and
3) precipitating the compound of Formula I in acetone to yield 1,4,7,10-tetraazacyclo-decane N,N', N",N'"-tetraacetic acid (DOTA) or 1,4,8,11-tetraazacyclotetradecane N,N',N",N'"-tetraacetic acid (TETA) in a yield over 90%.
2. The method of claim 1 further comprising derivatizing the product compound of Formula I by reacting the compound of Formula I with N-hydroxysuccinimide so that one carboxylic acid group on the compound of Formula I is derivatized as an activated ester yielding a compound of Formula IV ##STR15##
US08/042,249 1993-04-02 1993-04-02 Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging Expired - Lifetime US5428156A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US08/042,249 US5428156A (en) 1993-04-02 1993-04-02 Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/042,249 US5428156A (en) 1993-04-02 1993-04-02 Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US08/382,522 US5639879A (en) 1993-04-02 1995-02-02 Macrocyclic polyaminocarboxylates for stable radiometal antibody conjugates for therapy, spect and pet imaging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/382,522 Continuation US5639879A (en) 1993-04-02 1995-02-02 Macrocyclic polyaminocarboxylates for stable radiometal antibody conjugates for therapy, spect and pet imaging

Publications (1)

Publication Number Publication Date
US5428156A true US5428156A (en) 1995-06-27

Family

ID=21920861

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/042,249 Expired - Lifetime US5428156A (en) 1993-04-02 1993-04-02 Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US08/382,522 Expired - Lifetime US5639879A (en) 1993-04-02 1995-02-02 Macrocyclic polyaminocarboxylates for stable radiometal antibody conjugates for therapy, spect and pet imaging

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/382,522 Expired - Lifetime US5639879A (en) 1993-04-02 1995-02-02 Macrocyclic polyaminocarboxylates for stable radiometal antibody conjugates for therapy, spect and pet imaging

Country Status (1)

Country Link
US (2) US5428156A (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19646762A1 (en) * 1996-11-04 1998-05-07 Schering Ag Well tolerated diagnostic agent or radio-sensitiser
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US6517814B2 (en) 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
US6524372B1 (en) * 1998-01-26 2003-02-25 L′Air Liquide, Societe Anonyme a Directoire et Conseil de Surveillance pour l′Etude et l′Exploitation des Procedes Georges Claude Silica gel incorporating polyazacycloalkane structural units
US6565828B2 (en) 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US20040057900A1 (en) * 2001-02-23 2004-03-25 Edwards David Scott Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque
US6713046B1 (en) * 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
US6838557B1 (en) * 2002-10-01 2005-01-04 Board Of Regents The University Of Texas System Process for making a chelating agent for labeling biomolecules using preformed active esters
US20050002866A1 (en) * 1995-06-02 2005-01-06 Meade Thomas J. Magnetic resonance imaging agents for the detection of physiological agents
US6852854B1 (en) 2002-10-01 2005-02-08 Psiloquest Inc. Preformed carboxylated active ester for labeling biomolecules
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20060165600A1 (en) * 2002-09-06 2006-07-27 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health And Human Svcs. Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same
US20070021641A1 (en) * 2005-07-20 2007-01-25 Clear Vascular, Inc. Methods and compositions for treating luminal inflammatory disease
US20070071676A1 (en) * 2005-09-26 2007-03-29 Clear Vascular, Inc. Methods and Therapies for Treating Inflammatory Conditions with Exposed Collagen
US7354568B1 (en) 1997-10-27 2008-04-08 California Institute Of Technology Magnetic resonance imaging agents for the detection of physiological agents
EP2348052A2 (en) 2007-09-17 2011-07-27 The Regents of The University of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US20110237774A1 (en) * 2008-10-10 2011-09-29 Riken Method for introducing dota
US20120177569A1 (en) * 2009-09-17 2012-07-12 Hammersmith Imanet Lmited Labelled biotin conjugates
WO2012125582A1 (en) 2011-03-11 2012-09-20 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
CN103772307A (en) * 2012-10-18 2014-05-07 华东师范大学 Preparation method of DOTA.2HCl

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875864B2 (en) * 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20030007974A1 (en) * 2001-05-30 2003-01-09 Nanus David M. Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
AT535258T (en) * 2001-06-01 2011-12-15 Cornell Res Foundation Inc Modified antibodies against prostate-specific membrane antigen and their uses
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
CA2452288A1 (en) * 2001-09-20 2003-03-27 Cornell Research Foundation, Inc. Methods and compositions for treating and preventing skin disorders using binding agents specific for psma
EP3301114A1 (en) 2002-10-16 2018-04-04 Purdue Pharma LP Fusion polypeptides of antibodies that bind cell-associated ca 125/o722p
US20040136998A1 (en) * 2002-10-30 2004-07-15 Bander Neil H. Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
AU2003293556A1 (en) * 2003-01-10 2004-08-10 Millennium Pharmaceuticals, Inc. Methods of diagnosing and treating cancer
WO2005070456A2 (en) * 2004-01-09 2005-08-04 Millennium Pharmaceuticals, Inc. Diagnosing and treating female reproductive tract or chilhood cancer with pmsa antibodies
EP1610818A4 (en) * 2004-03-03 2007-09-19 Millennium Pharm Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US20180161464A1 (en) 2016-12-01 2018-06-14 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
US20180228926A1 (en) 2017-02-10 2018-08-16 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-lag3 antibodies for immuno-pet imaging
WO2019023148A1 (en) 2017-07-24 2019-01-31 Regeneron Pharmaceuticals, Inc. Anti-cd8 antibodies and uses thereof

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407645A (en) * 1943-06-21 1946-09-17 Martin Dennis Company Aliphatic polycarboxylic amino acids and process of making them
US4168265A (en) * 1977-05-19 1979-09-18 Iwao Tabushi Alkyl substituted cyclams
US4602106A (en) * 1984-03-26 1986-07-22 Societe Francaise Hoechst Process for producing hydroxyalkylaminoacetic acids
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4885153A (en) * 1985-05-17 1989-12-05 Neorx Corporation Radiohalogenated for proteins
US4889931A (en) * 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5021571A (en) * 1989-06-29 1991-06-04 Associated Universities, Inc. Cyclohexyl EDTA monoanhydride
US5049667A (en) * 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
US5082599A (en) * 1989-05-06 1992-01-21 Basf Aktiengesellschaft 2-methyl- and 2-hydroxymethyl-serine-n,n-diacetic acid and derivatives thereof
US5089663A (en) * 1989-06-29 1992-02-18 Associated Universities, Inc. Cyclohexyl-triethylenetetraamine hexacetic acid
US5101041A (en) * 1989-04-26 1992-03-31 The Curators Of The University Of Missouri Triamines and their derivatives as bifunctional chelating agents
US5132409A (en) * 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
DK172629B1 (en) * 1986-02-14 1999-03-22 Nihon Mediphysics Co Ltd Reactive high-molecular compounds having at least one free amino group, high molecular compounds in combination with a physiologically
US5064956A (en) * 1987-06-24 1991-11-12 The Dow Chemical Company Process for preparing mono-n-alkylated polyazamacrocycles
US5247075A (en) * 1987-08-12 1993-09-21 Celltech Limited Tri-aza macrocycles and metal complexes thereof
US5302700A (en) * 1988-05-23 1994-04-12 Duke University Radiohalogenation conjugate technology
US5075099A (en) * 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5342936A (en) * 1989-02-10 1994-08-30 David Parker Tetra-aza macrocycles and processes for their preparation
DE3938992A1 (en) * 1989-11-21 1991-05-23 Schering Ag Cascade polymer-bound complexing agent, the complex and conjugates, processes for their preparation and pharmaceutical compositions containing them
US5273743A (en) * 1990-03-09 1993-12-28 Hybritech Incorporated Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407645A (en) * 1943-06-21 1946-09-17 Martin Dennis Company Aliphatic polycarboxylic amino acids and process of making them
US4168265A (en) * 1977-05-19 1979-09-18 Iwao Tabushi Alkyl substituted cyclams
US4602106A (en) * 1984-03-26 1986-07-22 Societe Francaise Hoechst Process for producing hydroxyalkylaminoacetic acids
US4639365A (en) * 1984-10-18 1987-01-27 The Board Of Regents, The University Of Texas System Gadolinium chelates as NMR contrast agents
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US4880008A (en) * 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4885153A (en) * 1985-05-17 1989-12-05 Neorx Corporation Radiohalogenated for proteins
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US5132409A (en) * 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
US5049667A (en) * 1987-04-14 1991-09-17 Guerbet S.A. Nitrogen-containing cyclic ligands
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US4889931A (en) * 1988-09-27 1989-12-26 Salutar, Inc. Manganese (II) chelate manufacture
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
US5101041A (en) * 1989-04-26 1992-03-31 The Curators Of The University Of Missouri Triamines and their derivatives as bifunctional chelating agents
US5082599A (en) * 1989-05-06 1992-01-21 Basf Aktiengesellschaft 2-methyl- and 2-hydroxymethyl-serine-n,n-diacetic acid and derivatives thereof
US5089663A (en) * 1989-06-29 1992-02-18 Associated Universities, Inc. Cyclohexyl-triethylenetetraamine hexacetic acid
US5021571A (en) * 1989-06-29 1991-06-04 Associated Universities, Inc. Cyclohexyl EDTA monoanhydride

Non-Patent Citations (40)

* Cited by examiner, † Cited by third party
Title
C. F. Meares, et al. Br. J. Cancer 62(Suppl.X):21 26 (1990). *
C. F. Meares, et al. Br. J. Cancer 62(Suppl.X):21-26 (1990).
C. Wu, et al., Nucl. Med. Biol. 19:239 244 (1992). *
C. Wu, et al., Nucl. Med. Biol. 19:239-244 (1992).
Cox et al., J. Chem. Soc., Chem. Comm., 1989, pp. 797 798. *
Cox et al., J. Chem. Soc., Chem. Comm., 1989, pp. 797-798.
D. D. Dischino, et al., Inorg. Chem. 30: 1265 1269 (1991). *
D. D. Dischino, et al., Inorg. Chem. 30: 1265-1269 (1991).
J. F. Desreux, Inorg. Chem. 19:1319 1324 (1980). *
J. F. Desreux, Inorg. Chem. 19:1319-1324 (1980).
J. P. L. Cox et al., J. Chem. Soc. Chem. Commun. 1989: 797 798 (1989). *
J. P. L. Cox et al., J. Chem. Soc. Chem. Commun. 1989: 797-798 (1989).
M. J. McCall, et al., Bioconjugate Chem. 1:222 226 (1990). *
M. J. McCall, et al., Bioconjugate Chem. 1:222-226 (1990).
M. K. Moi and C. F. Meares, J. Am. Chem. Soc. 110:6266 6267 (1988). *
M. K. Moi and C. F. Meares, J. Am. Chem. Soc. 110:6266-6267 (1988).
M. K. Moi, et al., Analytical Biochemistry 148:249 253 (1986). *
M. K. Moi, et al., Analytical Biochemistry 148:249-253 (1986).
M. Magerstadt, et al., Magnetic Resonance in Medcine 3:808 812 (1986). *
M. Magerstadt, et al., Magnetic Resonance in Medcine 3:808-812 (1986).
Marsden, Solvents Guide, 1963, pp. 9 15. *
Marsden, Solvents Guide, 1963, pp. 9-15.
Mease, et al., J. Nucl. Med. 33:942 (May, 1992). *
O. A. Gansow, Nucl. Med. Biol. 18:369 381 (1991). *
O. A. Gansow, Nucl. Med. Biol. 18:369-381 (1991).
P. F. Sieving, et al., Bioconjugate Chem. 1:65 71 (1990). *
P. F. Sieving, et al., Bioconjugate Chem. 1:65-71 (1990).
R. G. Buckley and F. Searle, FEBS Letters 166: 202 204 (1984). *
R. G. Buckley and F. Searle, FEBS Letters 166: 202-204 (1984).
S. C. Srivastava et al., IXth International Symposium on Radiopharmaceutical Chemistry, Paris, France, Apr. 6 10, 1992. *
S. C. Srivastava et al., IXth International Symposium on Radiopharmaceutical Chemistry, Paris, France, Apr. 6-10, 1992.
S. C. Srivastava, et al., J. Nucl. Med. 33:1030 (May, 1992). *
S. J. Kline, Bioconjugate Chem. 2:26 31 (1991). *
S. J. Kline, Bioconjugate Chem. 2:26-31 (1991).
S. V. Deshpande, et al., J. Nucl. Med. 31:473 479 (1990). *
S. V. Deshpande, et al., J. Nucl. Med. 31:473-479 (1990).
Solomons, Organic Chemistry, 4th Ed., 1986, p. 849. *
The Merke Index, 11th Ed., 1989, p. 63. *
Wu et al., Nucl. Med. Biol. vol. 19(2), 1992, pp. 239 244. *
Wu et al., Nucl. Med. Biol. vol. 19(2), 1992, pp. 239-244.

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6120768A (en) * 1993-05-17 2000-09-19 Immunomedics, Inc. Dota-biotin derivatives
US20050002866A1 (en) * 1995-06-02 2005-01-06 Meade Thomas J. Magnetic resonance imaging agents for the detection of physiological agents
DE19646762B4 (en) * 1996-11-04 2004-05-13 Schering Ag Use of metal compounds for the preparation of agents for radiotherapy of tumors
DE19646762A1 (en) * 1996-11-04 1998-05-07 Schering Ag Well tolerated diagnostic agent or radio-sensitiser
US7354568B1 (en) 1997-10-27 2008-04-08 California Institute Of Technology Magnetic resonance imaging agents for the detection of physiological agents
US6713046B1 (en) * 1997-10-27 2004-03-30 Research Corporation Technologies Magnetic resonance imaging agents for the delivery of therapeutic agents
US6524372B1 (en) * 1998-01-26 2003-02-25 L′Air Liquide, Societe Anonyme a Directoire et Conseil de Surveillance pour l′Etude et l′Exploitation des Procedes Georges Claude Silica gel incorporating polyazacycloalkane structural units
US6565828B2 (en) 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
US6517814B2 (en) 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
US6974567B2 (en) 2001-02-23 2005-12-13 Bristol-Myers Squibb Pharma Company Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque
US20040057900A1 (en) * 2001-02-23 2004-03-25 Edwards David Scott Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque
US6869590B2 (en) 2001-02-23 2005-03-22 Bristol-Myers Squibb Pharma Company Labeled macrophage scavenger receptor antagonists for imaging atherosclerosis and vulnerable plaque
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
US7368100B2 (en) * 2002-09-06 2008-05-06 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Backbone-substituted bifunctional DOTA ligands, complexes and compositions thereof, and methods of using same
US20060165600A1 (en) * 2002-09-06 2006-07-27 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health And Human Svcs. Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same
US6852854B1 (en) 2002-10-01 2005-02-08 Psiloquest Inc. Preformed carboxylated active ester for labeling biomolecules
US6838557B1 (en) * 2002-10-01 2005-01-04 Board Of Regents The University Of Texas System Process for making a chelating agent for labeling biomolecules using preformed active esters
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US20070021641A1 (en) * 2005-07-20 2007-01-25 Clear Vascular, Inc. Methods and compositions for treating luminal inflammatory disease
US7874975B2 (en) 2005-07-20 2011-01-25 Clear Vascular, Inc. Methods and compositions for treating luminal inflammatory disease
US20070071676A1 (en) * 2005-09-26 2007-03-29 Clear Vascular, Inc. Methods and Therapies for Treating Inflammatory Conditions with Exposed Collagen
US9623129B2 (en) 2005-09-26 2017-04-18 Snip Holdings, Inc. Methods and therapies for treating inflammatory conditions with exposed collagen
EP2348052A2 (en) 2007-09-17 2011-07-27 The Regents of The University of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US20110237774A1 (en) * 2008-10-10 2011-09-29 Riken Method for introducing dota
US20120177569A1 (en) * 2009-09-17 2012-07-12 Hammersmith Imanet Lmited Labelled biotin conjugates
US8846001B2 (en) * 2009-09-17 2014-09-30 Ge Healthcare Limited Labelled biotin conjugates
WO2012125582A1 (en) 2011-03-11 2012-09-20 Board Of Regents Of The University Of Nebraska Biomarker for coronary artery disease
CN103772307A (en) * 2012-10-18 2014-05-07 华东师范大学 Preparation method of DOTA.2HCl

Also Published As

Publication number Publication date
US5639879A (en) 1997-06-17

Similar Documents

Publication Publication Date Title
EP0644778B1 (en) TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING
AU629172B2 (en) Coupling agents for radiolabeling proteins
AU638127B2 (en) A bifunctional dtpa-type ligand
AU681080B2 (en) Technetium-99m labeled peptides for imaging
JP2659351B2 (en) Polysubstituted diethylenetriamine and a manufacturing method thereof for forming protein complexes - metal chelates
CA1248090A (en) Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US6221334B1 (en) Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US5284644A (en) Functionalized polyamine chelants and rhodium complexes thereof for conjugation to antibodies
KR100235137B1 (en) Monoamine diamine thiol-containing metal chelating agents
AU595164B2 (en) Radiolabeled antibody fragments
CA2134092C (en) Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
US5585468A (en) Substituted thioureas as bifunctional chelators
EP0629617B2 (en) Heteroatom-bearing ligands and metal complexes thereof
Wu et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA
EP0279307B1 (en) Bifunctional chelating agents
US5489425A (en) Functionalized polyamine chelants
CA1328147C (en) Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
EP0772628B1 (en) Peptide derived radionuclide chelators
AU634167B2 (en) Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
EP0710228B1 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
EP0455268A1 (en) Biologically useful conjugates
EP0560947B1 (en) Trivalent monospecific antigen binding proteins
US5505931A (en) Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5175343A (en) Metal radionuclide labeled proteins for diagnosis and therapy
US6010680A (en) Thiolation of proteins for radionuclide-based radioimmunodetection and radioimmunotherapy

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION UNDERGOING PREEXAM PROCESSING

AS Assignment

Owner name: ASSOCIATED UNIVERSITIES, INC., DISTRICT OF COLUMBI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MEASE, RONNIE C.;MAUSNER, LEONARD F.;SRIVASTAVA, SURESH C.;REEL/FRAME:006741/0798;SIGNING DATES FROM 19930525 TO 19930527

AS Assignment

Owner name: BROOKHAVEN SCIENCE ASSOCIATES, NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASSOCIATED UNIVERSITIES, INC.;REEL/FRAME:009342/0184

Effective date: 19980317

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12